Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the central nervous system (CNS) is the next disease market where biomarkers will have the greatest impact on patient care and the overall drug market. Biomarkers have already had a significant impact in oncology and infectious disease markets.

"With the emerging promise of personalized medicine, biomarker development has been designated a priority by regulators, reflected in the large number of ongoing initiatives that involve industry, academia and regulatory agencies," stated Nitasha Manchanda, Ph.D., analyst at Decision Resources. "Indeed, the EMEA recently stated that biomarker data will be required for therapies seeking a full claim of disease modification in Alzheimer's and Parkinson's disease."

The new report entitled Emerging Biomarkers in CNS also finds that a diagnostic biomarker for Alzheimer's disease would have the largest impact on therapeutic sales. According to the report, the most valuable use for a biomarker in Alzheimer's disease is in identifying patients with early Alzheimer's or mild cognitive impairment, where diagnostic accuracy is lower. This diagnostic will impact the entire Alzheimer's market by increasing both the size of the diagnosed and drug-treated populations and the length of treatment.

In addition, the report's primary research from expert interviews and a survey of physicians reveals that neurologists prefer biomarkers that allow early diagnosis, while psychiatrists indicate a preference for biomarkers that will aid in predicting drug efficacy. However, emerging biomarkers in both neurology and psychiatry will face reimbursement hurdles as revealed by a survey of pharmacy/medical directors; all surveyed payers are considering implementing cost control measures for biomarker-based tests.

"Many hurdles still remain to be overcome before biomarkers in CNS can realize their full potential," added Sandra Chow, M.Sc., analyst at Decision Resources. "Drug developers have historically been wary of biomarkers because they threaten to reduce the use of their drug, regulators are warning of increased oversight of the field and payer reimbursement for novel tests remains problematic. Nevertheless, select neurologic and psychiatric indications hold high opportunity for biomarkers."

About the Report

Emerging Biomarkers in CNS presents extensive primary research with physicians, payers and biomarker specialists in the United States and Europe on the impact of biomarkers in neurologic and psychiatric markets. The report analyzes physician and payer attitudes toward biomarkers, the regulatory and reimbursement landscapes biomarkers will face, developmental strategies, biomarker technologies and indication-specific analysis of current and emerging biomarkers to provide a comprehensive view of biomarkers and their impact on the current and future market.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Natalia Morales                              Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563             

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,, or Elizabeth Marshall of Decision Resources, Inc.,

Horizon Blue's Conversion to For-Profit Status May Alter Plan's Existing Pricing Strategy

View Now